Induction of Parasite Growth-Inhibitory Antibodies by a Virosomal Formulation of a Peptidomimetic of Loop I from Domain III of Plasmodium falciparum Apical Membrane Antigen 1
Open Access
- 1 August 2003
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (8) , 4749-4758
- https://doi.org/10.1128/iai.71.8.4749-4758.2003
Abstract
Apical membrane antigen 1 (AMA-1) of Plasmodium falciparum is a leading candidate antigen for inclusion in a malaria subunit vaccine. Its ectodomain can be divided into three subdomains, each with disulfide bond-stabilized structures. Since the majority of antibodies raised against the ectodomain appear to recognize strain-specific epitopes in domain I, we attempted to develop a vaccine formulation which directs the immune response to a region that contains more conserved epitopes. Here we demonstrate that a virosomal formulation of a peptide that mimics the semiconserved loop I of domain III elicits parasite growth-inhibitory antibodies. A synthetic peptide comprising residues 446 to 490 of AMA-1 (AMA-1 446-490 ) was conjugated through the N terminus to a derivative of phosphatidylethanolamine and the phosphatidylethanolamine-peptide conjugate was incorporated into immunopotentiating reconstituted influenza virosomes as a human-compatible antigen delivery system. Both cyclized and linear versions of the peptide antigen elicited antibodies which specifically bound to parasite-expressed AMA-1 in Western blotting with parasite lysates as well as in immunofluorescence assays with blood stage parasites. All 11 peptidomimetic-specific monoclonal antibodies generated were cross-reactive with parasite-expressed AMA-1. Antigen binding assays with a library of overlapping cyclic peptides covering the target sequence revealed differences in the fine specificity of these monoclonal antibodies and provided evidence that at least some of them recognized discontinuous epitopes. The two immunodominant epitopes comprised the conserved linear sequences K 459 RIKLN 464 and D 467 DEGNKKII 475 . A key feature of the synthetic vaccine formulation proposed here is the display of the peptide antigen in a native-like state on the surface of the virosome.Keywords
This publication has 44 references indexed in Scilit:
- Progress and challenges for malaria vaccinesNature, 2002
- Proteolytic Processing and Primary Structure ofPlasmodium falciparum Apical Membrane Antigen-1Journal of Biological Chemistry, 2001
- Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum11Edited by J. A. WellsJournal of Molecular Biology, 2001
- Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasionMolecular and Biochemical Parasitology, 2000
- Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoelii YM Blood-Stage InfectionInfection and Immunity, 2000
- Diversity of the vaccine candidate AMA-1 of Plasmodium falciparumMolecular and Biochemical Parasitology, 1996
- Malarial haemozoin/β-haematin supports haem polymerization in the absence of proteinNature, 1995
- Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigenParasite Immunology, 1988
- Continuous and discontinuous protein antigenic determinantsNature, 1986
- Gamma-Globulin and Acquired Immunity to Human MalariaNature, 1961